Results 61 to 70 of about 17,658 (183)

Photodynamic therapy for neovascular age-related macular degeneration

Philippine Journal of Ophthalmology, 2005
Background: In neovascular age-related macular degeneration (ARMD) new vessels grow under the retina, distorting vision and leading to scarring. This is exacerbated if the blood vessels leak.
Richard P.L. Wormald, MA, MB, BCh, MSc, FRCS, FRCOphth, Jennifer R Evans, PhD, Katherine S Henshaw, Liam L Smeeth, MD   +3 more
doaj  

Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)

Clinical Ophthalmology, 2023
Liesbeth Van Cleemput,1,2 Freya Peeters,1,2 Julie Jacob1,2 1Department of Ophthalmology, University Hospital Leuven, Leuven, Belgium; 2Research Group Ophthalmology, Department of Neurosciences, KU Leuven, Leuven, BelgiumCorrespondence: Liesbeth Van ...
Van Cleemput L, Peeters F, Jacob J
doaj  

Development and Characterization of a Structurally Supportive of Hybrid PLGA Decellularized ECM Biomembrane for Ocular Progenitor Cell Anchorage and Epithelial Repair

Macromolecular Bioscience, Volume 26, Issue 8, August 2026.
Hybrid PLGA–corneal ECM biomembrane for ocular progenitor cell support and progenitor retinal cytoprotection. A hybrid biomembrane composed of PLGA and decellularized corneal extracellular matrix was developed to create a biomimetic microenvironment for ocular progenitor cells.
Ana Karulline Garcia Ungaratti, Aliny Pereira de Lima, Jordana Andrade Santos, Paula Leticia de Melo, Daniel Graziani, Artur Christian G. da Silva, Luis Antônio Dantas Silva, Marize Campos Valadares   +7 more
wiley   +1 more source

Advancing Treatment of Degenerative Eye Diseases at the Nanoscale

Smart Medicine, Volume 5, Issue 4, August 2026.
Nanotherapeutics possess the potential to overcome longstanding bottlenecks in treating degenerative ophthalmic diseases. With a highly tunable surface chemistry, nanotechnology platforms can be customized to navigate specific anatomical barriers in the eye and target pathways of diseases.
Li Yao Jin, Evashiniee G. P. Selvam, Qinsong Mei, Chi D. Luu, Yeannie H. Y. Yap, Daniel B. L. Teh   +5 more
wiley   +1 more source

Microenvironment‐Responsive Drug Delivery Systems for Ocular Surface Diseases: Mechanisms, Applications, and Translational Challenges

Small Science, Volume 6, Issue 8, August 2026.
Microenvironment‐responsive drug delivery systems overcome ocular physiological barriers by responding to temperature, pH, ions, reactive oxygen species, and enzymes. This review bridges material design, performance evaluation, and clinical translation, offering actionable insights for treating dry eye disease, infectious keratitis, and corneal ...
Jiamin Liu, Liangbo Chen, Yao Fu, Siyi Zhang   +3 more
wiley   +1 more source

Intravitreal bevacizumab for neovascular age-related macular degeneration

Philippine Journal of Ophthalmology, 2009
Objectives: Anti-vascular endothelial growth factor (anti-VEGF) drugs delivered intravitreally have been proven effective and safe for the treatment of patients diagnosed with neovascular age-related macular degeneration (ARMD).
Junn R. Pajarillo, MD, Harvey S. Uy,MD, Milagros H. Arroyo MD, MPH   +2 more
doaj  

Novel computer-based assessments of everyday visual function in people with age-related macular degeneration.

PLoS ONE, 2020
PurposeTo test the hypothesis that the performance in novel computer-based tasks of everyday visual function worsens with disease severity in people with non-neovascular age-related macular degeneration.MethodsParticipants with and without non ...
Bethany E Higgins, Deanna J Taylor, Wei Bi, Alison M Binns, David P Crabb   +4 more
doaj   +1 more source

Long‐term follow‐up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half‐dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4

Acta Ophthalmologica, Volume 104, Issue 5, Page e565-e577, August 2026.
Abstract Purpose Assessing the 24‐month treatment outcome of half‐dose photodynamic therapy (PDT) or oral eplerenone in chronic central serous chorioretinopathy (cCSC). Methods Multicentre randomized clinical trial included cCSC patients from the SPECTRA trial who were randomized to receive half‐dose PDT or oral eplerenone.
Helena M. A. Feenstra, Issam El Mansori, Thomas J. van Rijssen, Roula Tsonaka, Roselie M. H. Diederen, Carel B. Hoyng, Reinier O. Schlingemann, Camiel J. F. Boon, Elon H. C. van Dijk   +8 more
wiley   +1 more source

Cutting Edge Advancements in Management of Neovascular Age-Related Macular Degeneration A Scoping Review on Gene Therapy

IJRETINA (International Journal of Retina)
Introduction: Age-related macular degeneration (AMD) is the fourth leading cause of blindness globally. Therapeutic strategies for neovascular AMD (nAMD) have utilized anti-VEGF proteins, however compliance has become an issue. This study aims to explore
Diannisa Paramita Susantono, Andi Arus Victor   +1 more
doaj   +1 more source

Aqueous Humour Cytokines as Predictors of Axial Elongation in High Myopia: A 2‐Year Longitudinal Cohort Study

Clinical &Experimental Ophthalmology, Volume 54, Issue 6, Page 756-768, August 2026.
ABSTRACT Background To investigate the predictive value of aqueous humour cytokines for axial elongation. Methods This was a prospective longitudinal observational study. 72 high myopia patients (72 eyes) who received implantable collamer lens (ICL) implantation surgery with at least 2 years of follow‐up were included.
Lihui Meng, Yan Luo, Zhengming Shi, Youxin Chen, Zhikun Yang   +4 more
wiley   +1 more source